Periodical (Journal)

  1. PSIthority
  2. Library
  3. Periodicals
ISSN  :   1472-8222 ( Print )   |   1744-7631 ( Online )   Active

Expert Opinion on Therapeutic Targets

Aim & Scope
Expert Opinion on Therapeutic Targets (ISSN 1472-8222 [print], 1744-7631 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on novel molecular targets, providing expert opinion on the scope for future drug development and the impact on drug discovery. The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D. [1]

Go to Website

Continuations
(  1997  -  2001  ) Emerging Therapeutic Targets    (  2001  -  9999  ) Expert Opinion on Therapeutic Targets
Series / Collection
Active ( 2001  -  9999 ) Expert Opinion on Biological Therapy

1471-2598 ( Print )  1744-7682 ( Online ) 
Taylor and Francis Group ,  Ashley Publications Ltd. ,  Informa plc

250 3192
Active ( 2001  -  9999 ) Expert Opinion on Emerging Drugs

1472-8214 ( Print )  1744-7623 ( Online ) 
Taylor and Francis Group ,  Ashley Publications Ltd. ,  Informa plc

78 827
Active ( 1994  -  9999 ) Expert Opinion on Investigational Drugs

1354-3784 ( Print )  1744-7658 ( Online ) 
Taylor and Francis Group ,  Ashley Publications Ltd. ,  Informa plc

344 4110
Active ( 1999  -  9999 ) Expert Opinion on Pharmacotherapy

1465-6566 ( Print )  1744-7666 ( Online ) 
Taylor and Francis Group ,  Ashley Publications Ltd. ,  Informa plc

371 5302
Active ( 1994  -  9999 ) Expert Opinion on Therapeutic Patents

1354-3776 ( Print )  1744-7674 ( Online ) 
Taylor and Francis Group ,  Ashley Publications Ltd. ,  Informa plc

342 3373
Active ( 2001  -  9999 )

Expert Opinion on Therapeutic Targets

1472-8222 ( Print )  1744-7631 ( Online ) 
Taylor and Francis Group ,  Informa plc

225 2189
 
2022
9 RESULTS in 21 msec
Emerging drug targets for achondroplasia.

R Savarirayan

Expert Opinion on Therapeutic Targets , 2022 - VOLUME 26, ISSUE 5 , pp 1-3.

 
0 0
Small molecule neurolysin activators, potential multi-mechanism agents for ischemic stroke therapy.

SH Esfahani , TJ Abbruscato , PC Trippier , VT Karamyan

Expert Opinion on Therapeutic Targets , 2022 - VOLUME 26, ISSUE 5 , pp 1-4.

 
0 0
Progeria: a perspective on potential drug targets and treatment strategies.

I Benedicto , X Chen , MO Bergo , V Andrés

Expert Opinion on Therapeutic Targets , 2022 - VOLUME 26, ISSUE 5 , pp 1-7.

 
0 0
The mineralocorticoid receptor signal could be a new molecular target for the treatment of diabetic retinal complication.

K Ohashi , T Hayashi , K Utsunomiya , R Nishimura

Expert Opinion on Therapeutic Targets , 2022 - VOLUME 26, ISSUE 5 , pp 1-8.

 
0 0
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.

X Yang , P Feng , R Ji , ... , C Hölscher

Expert Opinion on Therapeutic Targets , 2022 - VOLUME 26, ISSUE 5 , pp 1-16.

 
0 0
Scavenger receptor A in immunity and autoimmune diseases: Compelling evidence for targeted therapy.

Y Xie , Y Jia , Z Li , F Hu

Expert Opinion on Therapeutic Targets , 2022 - VOLUME 26, ISSUE 5 , pp 1-17.

 
0 0
Fatty acid synthase: a druggable driver of breast cancer brain metastasis.

JA Menendez , R Lupu

Expert Opinion on Therapeutic Targets , 2022 - VOLUME 26, ISSUE 5 , pp 1-18.

 
0 0
Dapagliflozin mitigates ovalbumin-prompted airway inflammatory-oxidative successions and associated bronchospasm in a rat model of allergic asthma.

MME Tabaa , AMK Fattah , M Shaalan , ... , NA El Mahdy

Expert Opinion on Therapeutic Targets , 2022 - VOLUME 26, ISSUE 5 , pp 1-20.

 
0 0
Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.

X Xie , J Lee , T Iwase , ... , NT Ueno

Expert Opinion on Therapeutic Targets , 2022 - VOLUME 26, ISSUE 5 , pp 1-21.

 
0 0